ALVO
NASDAQ · Biotechnology
Alvotech Sa
$4.55
-0.12 (-2.57%)
Open$4.66
Previous Close$4.67
Day High$4.66
Day Low$4.51
52W High$6.53
52W Low$2.94
Volume—
Avg Volume721.7K
Market Cap1.90B
P/E Ratio—
EPS$-0.63
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+597.1% upside
Current
$4.55
$4.55
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 842.95M | 442.21M | 133.98M |
| Net Income | 39.95M | 18.86M | 26.13M |
| Profit Margin | 4.7% | 4.5% | 19.5% |
| EBITDA | 171.44M | 85.44M | 43.53M |
| Free Cash Flow | — | — | 33.36M |
| Rev Growth | +90.6% | +90.6% | +20.0% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |